🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. Odronextamab

    Regeneron UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 2 mab active

    1 trial

  2. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkin Lymphoma (B-NHL)

    phase 2 small molecule active

    2 trials

  3. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma

    phase 2 mab active

    1 trial

  4. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  5. Oxaliplatin

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  6. Pexastimogene Devacirepvec (Pexa-Vec)

    Regeneron UK Limited

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  7. Placebo

    Regeneron UK Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  8. Placebo

    Regeneron UK Limited

    Generalized Lipodystrophy

    phase 2 small molecule completed

    1 trial

  9. Placebo (for dupilumab)

    Regeneron UK Limited

    Nasal Polyps

    phase 2 small molecule completed

    1 trial

  10. R475

    Regeneron UK Limited

    Thermal Injury Pain

    phase 2 small molecule terminated

    1 trial

  11. REGN1033 (SAR391786)

    Regeneron UK Limited

    Sarcopenia

    phase 2 small molecule completed

    1 trial

  12. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  13. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule completed

    2 trials

  14. REGN13335

    Regeneron UK Limited

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  15. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  16. REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  17. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  18. REGN1908-1909

    Regeneron UK Limited

    Cat Allergy

    phase 2 small molecule completed

    1 trial

  19. REGN2176-3

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  20. REGN2477

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule completed

    1 trial

  21. REGN2477+REGN1033

    Regeneron UK Limited

    Sporadic Inclusion Body Myositis

    phase 2 small molecule terminated

    1 trial

  22. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  23. REGN3500

    Regeneron UK Limited

    Atopic Dermatitis

    phase 2 small molecule terminated

    2 trials

  24. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources